Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Recombinant antihemophilic factor plasma/albumin-free method blood products/substitutes data

Interim data from an open-label extension study in 27 patients with >=50

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE